Recombinant human interferon alpha-2b biosimilar - Tianjin Sinobioway Biomedicine

Drug Profile

Recombinant human interferon alpha-2b biosimilar - Tianjin Sinobioway Biomedicine

Alternative Names: Alfaron; Jaferon; rhIFNα2b

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tianjin Sinobioway Biomedicine
  • Developer Beijing Ditan Hospital Capital Medical University; Tianjin Sinobioway Biomedicine
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Condylomata acuminata; Hepatitis A; Hepatitis B; Herpes simplex virus infections; Leukaemia
  • Phase I Coxsackievirus infections

Most Recent Events

  • 07 Nov 2017 Launched for Condylomata acuminata in China (Topical) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)
  • 07 Nov 2017 Launched for Hepatitis A in China (Injection) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)
  • 07 Nov 2017 Launched for Hepatitis B in China (Injection) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top